Try our Advanced Search for more refined results
Life Sciences
-
April 21, 2026
Merck Beats Minn. Hockey Player's Talc Mesothelioma Claims
A Chicago jury has found Merck & Co. not liable for a hockey player's mesothelioma allegedly caused by the Dr. Scholl's talc foot powder he used regularly for years.
-
April 21, 2026
Biotech Co. Investors Clash Over 'Self-Dealing' Claim
Attorneys for a biopharmaceutical and technology company stockholder and a group of venture investors sharply disagreed Tuesday over whether a financing deal was a lifeline for a struggling company or a self-serving maneuver that enriched insiders, as they argued a motion to dismiss the derivative suit in the Delaware Chancery Court.
-
April 21, 2026
Congress Rallies More For Bills On Copyrights Than Patents
There have been more intellectual property bills floated in Congress that are supportive of copyright rights than patent rights, according to a new report looking at how lawmakers treat the IP system.
-
April 21, 2026
Amgen Faces ERISA Suit Over Health Plan Tobacco Surcharge
A former Amgen Inc. employee filed a proposed class action in California federal court Tuesday alleging the biotech company discriminatorily imposes an "egregiously high" $150-a-month surcharge on employees who use tobacco products, while failing to adequately notify them of reasonable pathways to avoid the fees, in violation of federal benefits law.
-
April 21, 2026
Pfizer, Dexcel Take 2 Patents Off Table For Bench Trial
Drugmaker Pfizer and an Israeli competitor that is seeking to create a generic version of a Pfizer heart medication said Tuesday they have reached an agreement to remove two asserted patents from a trial set to start next week.
-
April 21, 2026
Fed. Circ. Keeps Banner Witcoff And Saiber Off Patent Case
The Federal Circuit kept intact the disqualification of two law firms from a patent ownership fight on Tuesday, saying it had not been shown a district judge made a clear error in removing them.
-
April 21, 2026
Pot Management Co. Says It's Allowed Biz Tax Deduction
A California-based management company linked to cannabis operations is challenging the IRS over a $4.2 million tax bill, according to a U.S. Tax Court petition, arguing that the company does not traffic in controlled substances that would otherwise bar it from claiming business deductions.
-
April 21, 2026
Squires Stands By Ending Skincare IPR Over ITC Overlap
U.S. Patent and Trademark Office Director John Squires has shot down Sinclair Pharma Ltd.'s request to revive its challenge to Hydrafacial LLC's skin treatment patent, which the director had terminated based on related proceedings at the U.S. International Trade Commission.
-
April 21, 2026
Novo Nordisk Unit Can't Slip Former Exec's Sex, Age Bias Suit
A Novo Nordisk unit must face a former finance director's lawsuit claiming she was fired because she was an older woman who complained about a male co-worker's behavior, with a North Carolina federal judge ruling her allegations were detailed enough to stay in court.
-
April 21, 2026
Purdue Pharma Sentencing Punted For In-Person Attendance
A New Jersey federal judge delayed Oxycontin maker Purdue Pharma's criminal sentencing by a week, saying rescheduling would give an in-person attendance option to hundreds of observers who tuned in virtually Tuesday.
-
April 21, 2026
Ga. Justices Confront Fed, State Power Divide In Bio-Lab Suit
Georgia's highest court seemed to struggle Tuesday with whether it had the authority to tell a federal judge if residents suing chlorine products company Bio-Lab Inc. over the aftermath of a 2024 fire could ask for medical monitoring as part of their class action.
-
April 21, 2026
Philly Zantac Judge Again Declines To Recuse From Cases
A Philadelphia judge overseeing the Zantac mass tort litigation against GlaxoSmithKline has once again denied a motion to recuse himself from the cases, claiming that his wife's affiliation with a firm representing a defendant in the litigation did not present a conflict that required him to step away.
-
April 20, 2026
Armistice Head Testifies He Accidentally Deleted Texts
Armistice Capital's founder, who is facing investor claims that the hedge fund dumped its artificially inflated shares in pharmaceutical company Vaxart for $250 million, told a California federal jury Monday that during a physical therapy session held over Skype, he accidentally deleted key text messages with another Armistice executive.
-
April 20, 2026
Beasley Allen Pro Hac Vice Revoked In Philly J&J Talc Cases
A Pennsylvania state court has booted Beasley Allen Law Firm attorneys from representing consumers in nine cases that link Johnson & Johnson's talcum powder to ovarian cancer, saying their pro hac vice admission was inappropriate given the firm's dealings with an attorney who previously represented the company.
-
April 20, 2026
Quinn Emanuel May Face More Sanctions In Guardant Fight
Guardant Health Inc. urged a California federal judge on Monday to make Quinn Emanuel pay nearly $1.3 million on top of $3 million in sanctions already imposed over misrepresentations lawyers made representing its rival Natera Inc., prompting the judge to criticize Quinn Emanuel lawyers for making distinctions so fine they veer into misrepresentation.
-
April 20, 2026
Philip Morris Unfairly Gains From Label Ruling, 11th Circ. Told
Philip Morris cannot be the only company allowed to not follow a rule requiring cigarette makers to add graphic warnings to their labels, R.J. Reynolds and a coalition of tobacco businesses have told the Eleventh Circuit, suggesting that consumers might assume its cigarettes are safer than theirs.
-
April 20, 2026
ImmunityBio Stock Fell After FDA Letter, Derivative Suit Says
Biotechnology company ImmunityBio Inc.'s stock slipped by 21% after misleading statements on a podcast by the company's founder about its lead cancer drug prompted the issuance of a warning letter from the U.S. Food and Drug Administration, according to a shareholder derivative suit in California federal court.
-
April 20, 2026
SEC Says Adviser Traded On Firm Clients' Confidential Info
The U.S. Securities and Exchange Commission sued an ex-investment advisory firm associate in Manhattan federal court on Monday, accusing him of using a close relative's brokerage account to trade ahead of market-moving announcements by three biopharmaceutical and biotechnology companies that his firm was researching.
-
April 20, 2026
PFAS Plaintiffs Say Midcase Appeal Would 'Derail' Litigation
Georgia residents accusing carpet and chemicals manufacturers of contaminating their properties with forever chemicals urged a state court to reject Shaw Industries' bid to appeal the recent nondismissal of their claims, arguing the request is the carpet company's latest "attempt to derail this litigation."
-
April 20, 2026
PBMs Fail To Freeze Discovery In Mich.'s Drug-Pricing Case
A pending motion to dismiss the Michigan attorney general's drug-pricing case against multiple pharmacy benefit managers does not preclude the PBMs from handing over agreements between PBMs and pharmacies to the state, a federal judge said in a motion hearing Monday.
-
April 20, 2026
She Has A Point: Fish & Richardson's Nitika Gupta Fiorella
Fish & Richardson PC principal Nitika Gupta Fiorella is "a no-stone-unturned, always super prepared" lawyer who "epitomizes professionalism and respect," according to Finnegan Henderson Farabow Garrett & Dunner LLP partner Cora Holt.
-
April 20, 2026
Doctors Fueled Man's Fatal Opioid Addiction, Philly Jury Told
Counsel for the family of a man who died of an opioid overdose at age 26 told a Philadelphia jury that his doctors were responsible for pushing treatment plans that allowed him to develop an opioid addiction, leading to his untimely death, pointing to both physicians being paid speakers for the pharmaceutical companies whose medications they prescribed.
-
April 20, 2026
Justices Mull Limits On Federal Review Of State Cases
The U.S. Supreme Court on Monday wrestled with the potential impact of reining in — or even scrapping altogether — a 100-year-old doctrine that curbs litigants' ability to go to federal court to try to overturn a state court loss.
-
April 20, 2026
House Panel Probes Reports Of Missing, Killed Scientists
Two Republican U.S. congressmen announced a probe Monday into reports of about a dozen scientists or government employees with ties to American nuclear and space programs who were killed or reported missing, penning letters seeking information from NASA, the Department of Energy, the FBI and the Defense Department.
-
April 20, 2026
GSK, Moderna Both Ordered To Provide More Info In Vax Fight
A special master overseeing discovery disputes in GlaxoSmithKline's infringement suits over Moderna's COVID-19 and related respiratory syncytial virus vaccines ordered both companies to furnish information to each other, including financial data and licenses, according to an opinion unsealed Monday.
Expert Analysis
-
Getting The Most Out Of Learning And Development Programs
Excerpt from Practical Guidance
Junior associates can better develop the legal, business and interpersonal skills they need for long-term success by approaching their firms’ learning and development programs armed with five tips for getting the most out of these resources, says Lauren Hakala at Reed Smith.
-
Opinion
AI Presents A Make-Or-Break Moment For Outside Counsel
The rapid adoption of artificial intelligence by corporate legal departments is forcing a long-overdue reset of the relationship between inside and outside counsel, and introducing a significant opportunity to shed frustrating inefficiencies and strengthen collaboration for firms willing to embrace the shift, says Intel Chief Legal Officer April Miller Boise.
-
Opinion
USPTO Has A Chance To Correct Double-Patenting Doctrine
Now that the issue of obviousness-type double patenting is front and center before the U.S. Patent and Trademark Office's Appeals Review Panel, the agency should put an end to the practice of rejecting earlier-expiring patents in favor of later-expiring ones, say attorneys at Orrick.
-
Navigating Life Sciences Deals Amid Heightened Scrutiny
With pricing reform initiatives, national security legislation and evolving trade policy currently contributing to meaningful uncertainty for life sciences companies, it is important to proactively structure deals to avoid downstream complications, say attorneys at Cooley.
-
Series
Watching Hallmark Movies Makes Me A Better Lawyer
I realize you may be judging me for watching, and actually enjoying, Hallmark Channel movies, but the escapism and storylines actually demonstrate qualities and actions that lead to an efficient, productive and positive legal practice, says Karen Ross at Tucker Ellis.
-
New Orphan Drug Law Provides A Key Fix For Pharma Cos.
The Consolidated Appropriations Act enacted last month restores the U.S. Food and Drug Administration's long-standing interpretation of "same disease or condition," related to orphan drug exclusivity, resolving years of regulatory uncertainty and litigation that have discouraged rare disease research, say attorneys at Spencer Fane.
-
When Trade Secret Litigation And Criminal Law Collide
An increasing convergence of trade secret litigation and white collar defense, especially with several recent criminal prosecutions from the Justice Department, should prompt businesses and counsel to adapt within the overlapping landscapes, says Kenneth Notter at MoloLamken.
-
Opinion
PTAB Needs Reform To Protect Inventors From Larger Cos.
The Promoting and Respecting Economically Vital American Innovation Leadership Act is necessary because it will impose additional requirements on patent validity challenges and prevent large corporations from taking advantage of the Patent Trial and Appeal Board to overwhelm small inventors with repeated litigation, says Eb Bright at ExploraMed Development.
-
FDA User Fee Talks Offer Clues On Upcoming Reforms
As the U.S. Food and Drug Administration undergoes the User Fee Act reauthorization process and renegotiates its user fee agreements over the next several months, the agency's consultation meetings with relevant industries can shed light on the FDA's priorities, and provides stakeholders an opportunity to participate in the reform process, say attorneys at Holland & Knight.
-
Moderna Case Highlights Overlooked Hurdle In Biopharma IP
The recent settlement of the patent litigation involving Moderna's COVID-19 vaccine in Delaware federal court shows that patent portfolios covering enabling platform technologies can create significant freedom-to-operate risk even when their owners are not direct competitors developing the therapeutic product, says Olga Berson at Thompson Coburn.
-
FDA Framework For Personalized Therapies Raises Questions
The U.S. Food and Drug Administration's new plausible mechanism framework for developing individualized therapies reflects the agency's focus on rare-disease drugs, but numerous significant, unresolved issues cast uncertainty on how effective the framework will be in practice, say attorneys at Ropes & Gray.
-
Emissions Permits May Not Override Pollution Exclusions
Two recent coverage rulings from the Illinois Supreme Court and the Third Circuit suggest a trend among appellate courts to deny coverage under pollution exclusions, even when the emissions happened pursuant to a government permit, say attorneys at Simpson Thacher.
-
5 Tips For Navigating Your Firm's All-Attorney Summit
Excerpt from Practical Guidance
Law firm retreats should be approached strategically, as they present valuable opportunities to advance both the firm's objectives and attorneys' professional development through meaningful participation, building and strengthening internal relationships, and proactive follow-up, says James Argionis at Cozen O’Connor.
-
Series
Coaching Soccer Makes Me A Better Lawyer
Coaching youth soccer for my 7-year-old son's team has sharpened how I communicate with clients, prepare witnesses, work within teams and think about leadership, making me a more thoughtful and effective lawyer in many ways, says Joshua Holt at Smith Currie.
-
Series
Law School's Missed Lessons: The Human Element
Law school teaches you to quickly apply intellect and logic when handling a legal issue, but every fact pattern also involves a person, making the ability to balance expertise with empathy critical to the growth of relationships with clients, colleagues and adversaries, says Rachel Adcox at Adcox Strategies.